MX2020011712A - Vacunas de nanoparticulas multivalentes contra la influenza. - Google Patents

Vacunas de nanoparticulas multivalentes contra la influenza.

Info

Publication number
MX2020011712A
MX2020011712A MX2020011712A MX2020011712A MX2020011712A MX 2020011712 A MX2020011712 A MX 2020011712A MX 2020011712 A MX2020011712 A MX 2020011712A MX 2020011712 A MX2020011712 A MX 2020011712A MX 2020011712 A MX2020011712 A MX 2020011712A
Authority
MX
Mexico
Prior art keywords
influenza
disclosed
multivalent
nanoparticle vaccines
multivalent influenza
Prior art date
Application number
MX2020011712A
Other languages
English (en)
Inventor
Gale Smith
Sarathi Boddapati
Anushree Herwadkar
Jason Wong
Yen - Huei Lin
Jing - Hui TIAN
Original Assignee
Novavax Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novavax Inc filed Critical Novavax Inc
Publication of MX2020011712A publication Critical patent/MX2020011712A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16171—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16271—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

En el presente documento se describen composiciones de vacuna de nanopartículas multivalentes adecuadas para su uso en vacunas contra la influenza. Las nanopartículas incluyen cantidades eficaces de glicoproteínas de la influenza que proporcionan una mayor respuesta inmunitaria en comparación con una composición de vacuna contra la influenza disponible comercialmente. La presente descripción también proporciona estrategias de formulación de vacunas que son rentables y convenientes para uso clínico. También se describen métodos para administrar las composiciones de vacuna de nanopartículas a un sujeto.
MX2020011712A 2018-03-19 2020-09-17 Vacunas de nanoparticulas multivalentes contra la influenza. MX2020011712A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862644623P 2018-03-19 2018-03-19
US201962787980P 2019-01-03 2019-01-03

Publications (1)

Publication Number Publication Date
MX2020011712A true MX2020011712A (es) 2021-01-08

Family

ID=67987992

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020009682A MX2020009682A (es) 2018-03-19 2019-03-19 Vacunas de nanoparticulas multivalentes contra la influenza.
MX2020011712A MX2020011712A (es) 2018-03-19 2020-09-17 Vacunas de nanoparticulas multivalentes contra la influenza.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2020009682A MX2020009682A (es) 2018-03-19 2019-03-19 Vacunas de nanoparticulas multivalentes contra la influenza.

Country Status (12)

Country Link
US (2) US11278612B2 (es)
EP (1) EP3768308A4 (es)
JP (1) JP7417532B2 (es)
KR (1) KR20210004959A (es)
CN (1) CN112469436A (es)
AU (1) AU2019238171A1 (es)
BR (1) BR112020019108A2 (es)
CA (1) CA3092984A1 (es)
IL (2) IL305911A (es)
MX (2) MX2020009682A (es)
SG (1) SG11202009206QA (es)
WO (1) WO2019183063A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10426829B2 (en) 2015-09-03 2019-10-01 Novavax, Inc. Vaccine compositions having improved stability and immunogenicity
SG11202009206QA (en) 2018-03-19 2020-10-29 Novavax Inc Multivalent influenza nanoparticle vaccines
WO2021214339A2 (en) 2020-04-24 2021-10-28 Acm Biolabs Pte Ltd Vaccine against human-pathogenic coronaviruses
AU2022270082A1 (en) * 2021-05-05 2023-11-16 Novavax, Inc. Coronavirus and influenza compositions and methods for using them

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
US5149650A (en) 1986-01-14 1992-09-22 University Of North Carolina At Chapel Hill Vaccines for human respiratory virus
ATE71303T1 (de) 1986-01-14 1992-01-15 Nederlanden Staat Verfahren zur herstellung immunologischer komplexe und diese enthaltende pharmazeutische zusammensetzung.
CA1331443C (en) 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
NL9002314A (nl) 1990-10-23 1992-05-18 Nederlanden Staat Immunogene complexen, in het bijzonder iscoms.
ES2370937T3 (es) 1993-09-13 2011-12-23 Protein Sciences Corporation Un método para producir vacunas antigripales polivalentes a base de hemaglutinina.
AUPM873294A0 (en) * 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
SE9600647D0 (sv) 1996-02-21 1996-02-21 Bror Morein Ny användning
US6231859B1 (en) 1996-12-02 2001-05-15 Aquila Biopharmaceuticals, Inc. Saponin adjuvant compositions
AUPO517897A0 (en) 1997-02-19 1997-04-11 Csl Limited Chelating immunostimulating complexes
US6558670B1 (en) 1999-04-19 2003-05-06 Smithkline Beechman Biologicals S.A. Vaccine adjuvants
EP1263461A4 (en) 2000-03-07 2009-08-12 Merck & Co Inc ADENOVIRUS FORMULATIONS
WO2002028426A1 (en) 2000-10-02 2002-04-11 Glaxosmithkline Biologicals S.A. Split enveloped virus preparation
SE0201750D0 (sv) 2002-06-06 2002-06-06 Chalmers Technology Licensing Selective Chromophores
SE0202110D0 (sv) 2002-07-05 2002-07-05 Isconova Ab Iscom preparation and use thereof
MXPA05011268A (es) 2003-04-25 2006-06-20 Medimmune Vaccines Inc Sistemas de expresion de virus de parainfluenza recombinante y vacunas que comprenden antigenos heterologos derivados del metaneumovirus.
SE0301998D0 (sv) 2003-07-07 2003-07-07 Isconova Ab Quil A fraction with low toxicity and use thereof
EP1713824A2 (en) 2003-12-10 2006-10-25 The Uab Research Foundation Recombinant viruses with heterologous envelope proteins
AU2005334514B2 (en) 2004-10-29 2009-11-26 President And Fellows Of Harvard College Particles for treatment of pulmonary infection
WO2006060710A2 (en) 2004-12-02 2006-06-08 Becton, Dickinson And Company Vaccine formulations for intradermal delivery comprising adjuvants and antigenic agents
US8252756B2 (en) 2005-06-14 2012-08-28 Northwestern University Nucleic acid functionalized nanoparticles for therapeutic applications
ES2564241T3 (es) 2005-12-02 2016-03-21 Glaxosmithkline Biologicals Sa Nanopartículas para su uso en composiciones inmunogénicas
ES2369608T3 (es) 2006-04-13 2011-12-02 Midatech Ltd. Nanopartículas que contienen tres ligandos diferentes para proporcionar respuestas inmunitarias frente a agentes infecciosos.
CA2655929A1 (en) 2006-06-19 2007-12-27 Progenics Pharmaceuticals, Inc. Processes for recovering stabilized formulations of trimers of retroviral envelope (env) proteins
WO2008061243A2 (en) 2006-11-16 2008-05-22 Novavax, Inc. Respiratory syncytial virus-virus like particle (vlps)
WO2008133663A2 (en) 2006-11-30 2008-11-06 Government Of The United States Of America, As Represented By The Secretary, Codon modified immunogenic compositions and methods of use
CN101553252A (zh) * 2006-12-06 2009-10-07 诺华有限公司 包含来自于四株流感病毒的抗原的疫苗
CA2684578A1 (en) 2007-03-21 2008-09-25 Id Biomedical Corporation Of Quebec Chimeric antigens
PL2540312T3 (pl) 2007-07-19 2015-10-30 Novavax Inc Chimeryczne VLP ptasiej grypy
AU2008310312B2 (en) * 2007-10-12 2013-12-19 Csl Limited Method of eliciting an immune response against pandemic influenza virus
US20100239671A1 (en) 2007-11-06 2010-09-23 Edelman Elazer R Tissue-Engineered Endothelial and Epithelial Implants Differentially and Synergistically Regulate Tissue Repair
EP4108688A1 (en) 2007-12-24 2022-12-28 ID Biomedical Corporation of Quebec Recombinant rsv antigens
WO2009108689A1 (en) 2008-02-25 2009-09-03 Novavax, Inc. Sugar glassified virus like particles (vlps)
US11446374B2 (en) 2008-12-09 2022-09-20 Novavax, Inc. Modified RSV F proteins and methods of their use
US8715692B2 (en) 2008-12-09 2014-05-06 Novavax, Inc. Modified RSV F proteins and methods of their use
MX350667B (es) 2009-05-27 2017-09-12 Selecta Biosciences Inc Nanoportadores que poseen componentes con diferentes tasas de liberacion.
CN102470168A (zh) 2009-07-10 2012-05-23 伊斯克诺瓦公司 新组合物
SG178026A1 (en) 2009-07-15 2012-03-29 Novartis Ag Rsv f protein compositions and methods for making same
AU2011235220B2 (en) 2010-03-30 2016-03-10 Mount Sinai School Of Medicine Influenza virus vaccines and uses thereof
CN103282023B (zh) 2010-11-05 2018-09-21 诺瓦瓦克斯股份有限公司 狂犬病糖蛋白病毒样颗粒(vlp)
CN102107003A (zh) 2011-01-05 2011-06-29 重庆大学 一种猪繁殖与呼吸综合症病毒体疫苗及其制备方法
CA2841047A1 (en) 2011-07-06 2013-01-10 Novartis Ag Immunogenic compositions and uses thereof
SG11201400999VA (en) 2011-09-30 2014-07-30 Novavax Inc Recombinant nanoparticle rsv f vaccine for respiratory syncytial virus
US20140037680A1 (en) 2012-08-06 2014-02-06 Glaxosmithkline Biologicals, S.A. Novel method
CA2900489A1 (en) 2013-02-11 2014-08-14 Novavax, Inc. Combination vaccine for respiratory syncytial virus and influenza
RU2531235C2 (ru) 2013-02-15 2014-10-20 Общество с ограниченной ответственностью "Универсальные БиоСистемы" (ООО "УБС") Поливалентная вакцина против гриппа на основе гибридного белка
EA035522B1 (ru) 2013-04-25 2020-06-29 Янссен Вэксинс Энд Превеншн Б.В. Стабильные растворимые f-полипептиды rsv в конформации "до слияния"
RU2685185C2 (ru) 2013-09-19 2019-04-16 Новавакс, Инк. Иммуногенные композиции коронавируса ближневосточного респираторного синдрома (mers-cov) и способы
CN104740609A (zh) * 2013-12-31 2015-07-01 上海中信国健药业股份有限公司 一种受体抗体融合蛋白的药物组合物
AU2014100888A4 (en) 2014-08-07 2014-09-11 Novartis Ag Virus clearance and protein purification methods
US20160045574A1 (en) 2014-08-18 2016-02-18 Tamir Biotechnology, Inc. Antiviral pharmaceutical for topical administration
EP3344288A1 (en) 2015-09-02 2018-07-11 Janssen Vaccines & Prevention B.V. Stabilized viral class i fusion proteins
US10426829B2 (en) 2015-09-03 2019-10-01 Novavax, Inc. Vaccine compositions having improved stability and immunogenicity
SG11202009206QA (en) 2018-03-19 2020-10-29 Novavax Inc Multivalent influenza nanoparticle vaccines

Also Published As

Publication number Publication date
RU2020130610A (ru) 2022-03-17
US11278612B2 (en) 2022-03-22
IL277274B1 (en) 2023-10-01
US20220080039A1 (en) 2022-03-17
SG11202009206QA (en) 2020-10-29
CN112469436A (zh) 2021-03-09
EP3768308A1 (en) 2021-01-27
IL277274A (en) 2020-10-29
IL277274B2 (en) 2024-02-01
US20190314487A1 (en) 2019-10-17
JP2021518353A (ja) 2021-08-02
JP7417532B2 (ja) 2024-01-18
US11896662B2 (en) 2024-02-13
IL305911A (en) 2023-11-01
EP3768308A4 (en) 2022-01-26
KR20210004959A (ko) 2021-01-13
CA3092984A1 (en) 2019-09-26
BR112020019108A2 (pt) 2020-12-29
AU2019238171A1 (en) 2020-09-24
MX2020009682A (es) 2020-10-12
WO2019183063A1 (en) 2019-09-26

Similar Documents

Publication Publication Date Title
MX2020011712A (es) Vacunas de nanoparticulas multivalentes contra la influenza.
CL2019003264A1 (es) Formulaciones para vacunas contra la neoplasia y métodos para preparar las mismas. (divisional solicitud 201703151)
CY1121789T1 (el) Νεες ανοσοενισχυτικες συνθεσεις
MX2017009308A (es) Composiciones inmunogenicas para usar en vacunas neumococicas.
CL2018000320A1 (es) Coadyuvantes basados en aceite (divisional de solicitud 201600650)
EP4218807A3 (en) Zika virus vaccine
MX2019008564A (es) Composiciones inmunogenicas para su uso en vacunas neumococicas.
MX2017014538A (es) Regimenes de cebado-refuerzo que implican la administracion de al menos un constructo de arnm.
BR112015008417A8 (pt) composição imunogênica, vacina, e, uso de uma composição imunogênica
WO2016019134A8 (en) Flagellin-based agents and uses including effective vaccination
EP3616716A3 (en) Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
NZ714163A (en) Novel immunotherapy against several tumors, such as lung cancer, including nsclc
TR201904758T4 (tr) İmmünoterapiye yönelik RNA formülasyonu.
MY189495A (en) Hand, foot, and mouth vaccines and methods of manufacture and use thereof
MX2018004616A (es) Cosmetica qie tiene bacterias probioticas.
MX346094B (es) Método de administración de vacunas.
MX2013014485A (es) Vacuna bovinas y metodos.
MX2018015361A (es) Formulacion de vacuna contra el vih.
PH12015501716B1 (en) Anti-mycoplasma spp. subunit vaccine
BRPI0918806A2 (pt) composição compreendendo quitosana para administração ocular de vaninas em aves
MX2015007753A (es) Composicion de vacunas para sujetos intactos.
WO2014205199A3 (en) Compositions and methods for potentiating immune response, enhancing immunotherapy, and increasing vaccine potency
CO6561819A2 (es) Vectores para vacunas y método para potenciar respuestas inmunes
CU20180025A7 (es) Proceso de preparación de una vacuna tetravalente atenuada contra el virus del dengue
NZ731659A (en) Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus